Bryan Garnier initiated coverage of Crispr Therapeutics with a Buy rating and $70 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
- Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed
- CRISPR Therapeutics Announces Transition of Chief Financial Officer
- Baird starts Crispr at Neutral with strong launch priced in
- Crispr Therapeutics initiated with a Neutral at Baird